Navigation Links
Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP
Date:6/19/2013

Santa Ana, CA (PRWEB) June 19, 2013

McGuff Pharmaceuticals, Inc. continues to pursue the approval of an Abbreviated New Drug Application (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, 5mL, multiple dose vial; a generic version of Bristol-Myers Squibb’s drug fomerly known as Delalutin™. We are providing this update in response to varied inquiries regarding the anticipated approval and market introduction dates for McGuff’s Hydroxyprogesterone Caproate Injection, USP drug product.

Regarding the status of our pending ANDA, to date, McGuff has responded to all Food and Drug Administration (FDA) inquiries concerning the ANDA submitted in October 2009. While we are hopeful that a final decision will be made soon, McGuff can not predict when the Agency will make it’s final determination concerning the ANDA approval. We remain committed to bringing Hydroxyprogesterone Caproate Injection, USP to market as quickly as possible.

Our commitment to bring cost effective branded and generic injectable drugs to the U.S. and International markets, for the benefit of patients in need, continues to be one of our driving principles.

If you would like more information about this topic or to schedule an interview with Damon P. Jones, Vice President of McGuff Pharmaceuticals, Inc., please contact Maureen French at 800-603-4795 x301 or email mfrench(at)mcguff(dot)com. You may also visit our website at http://www.mcguffpharmaceuticals.com.

About McGuff Pharmaceuticals, Inc.

McGuff Pharmaceuticals is a Food and Drug Administration (FDA) inspected sterile fill manufacturer that maintains a tradition of quality and core competency in both FDA current Good Manufacturing Practices (cGMP) and International Organization for Standardization’s Quality Management Systems (ISO) 9001:2008, a unique combination for any pharmaceutical manufacturer.

The McGuff family of companies provides commercial pharmaceuticals, compounded drugs, nutritional supplements, medical products and contract services used by leading healthcare organizations and professionals.

The McGuff family of companies includes:

McGuff Company, Inc. – Corporate Headquarters and Medical Products Distribution Center

Subsidiaries:

McGuff Pharmaceuticals, Inc. – Commercial drug manufacturing
McGuff Medical Canada, Inc. – Medical products distribution
McGuff Compounding Pharmacy Services, Inc. – Pharmacy and Compounded drugs

Read the full story at http://www.prweb.com/releases/2013/6/prweb10833717.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. PET/MR effective for imaging recurrent prostate cancer
2. ENT and Allergy Associates®, LLP Is Bullish on Wall Street; Practice to Expand/Upgrade Current Clinical Office at 150 Broadway in NYC
3. Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies
4. Poliovirus vaccine trial shows early promise for recurrent glioblastoma
5. Hound.com Finds Jobs in South Atlantic and South West Central Regions Mirroring Current Employment Trends
6. Apple Products are Currently Marked Down at SportsFanPlayground.com
7. Seeking Damages From Bullies: New Website, Bullying Decoded, Reviews Current Legal Cases and Statutes
8. Minimal dose CT superior to chest X-ray for detection of recurrent lung cancer
9. Study reports adenoma detection rates are higher than current guidelines suggest in both men and women
10. Current HPV vaccine may not help some women with immune problems
11. Global burden of dengue is triple current estimates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: